Company Filing History:
Years Active: 2010-2013
Title: The Innovations of Sushil Chandra Jha: A Pioneer in Pharmaceutical Chemistry
Introduction: Sushil Chandra Jha, located in Hull, GB, is an innovative inventor who has contributed significantly to the field of pharmaceutical chemistry. With a total of two registered patents, Jha's work highlights the intersection of medicinal chemistry and neuroscience.
Latest Patents: One of Jha's notable recent patents is for "Substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives." This invention introduces novel compounds that exhibit binding affinities towards serotonin receptors, particularly 5-HT and 5-HT receptors, as well as dopamine receptors, especially dopamine D2 receptors. The compounds are characterized by their norepinephrine reuptake inhibition properties, making them valuable in the pharmaceutical industry. The invention aims to provide pharmaceutical compositions that can be utilized in treating a variety of psychiatric and neurological disorders, including specific psychotic, cardiovascular, and gastrokinetic conditions. The compounds can be represented by a general formula, which includes pharmaceutically acceptable acid or base addition salts, stereochemically isomeric forms, N-oxide forms, and prodrugs.
Career Highlights: Sushil Chandra Jha works at Janssen Pharmaceutica NV, a prominent pharmaceutical company known for its commitment to innovation in drug development. Jha's contributions in drug formulation are paramount, particularly in understanding psychiatric and neurological disorders.
Collaborations: Throughout his career, Jha has collaborated with esteemed colleagues such as José Maria Cid-Núñez and Andrés Avelino Trabanco-Suárez. These collaborations have further enhanced the scope and impact of his research and innovations.
Conclusion: Sushil Chandra Jha stands as a notable figure in the realm of pharmaceutical inventions. His work in developing new medicinal compounds demonstrates a profound impact on the treatment of psychiatric and neurological disorders. As advancements continue, Jha's contributions will likely pave the way for future innovations in the field.